Instructions Specific to This Exam

1. This examination contains one question worth a total of 100 marks.

2. You will be assessed primarily on your knowledge of the relevant constitutional provisions, cases and assigned materials identified in the Canadian Constitutional Law syllabus, together with your ability to recognize the constitutional issues raised by the facts and analyze the competing arguments relevant to those issues.

3. No marks are awarded for merely reproducing or summarizing the facts. You are expected to identify the relevant constitutional issues, state the governing legal rules and apply those rules closely to the facts.

4. Do not provide a general essay on Canadian constitutional law or work through a memorized checklist of constitutional doctrines that are not reasonably raised by the facts.

5. Full citations are not required for cases contained in the assigned materials. However, where an assigned authority is relevant, identify it with sufficient precision to demonstrate knowledge of the governing law.

6. You are asked to prepare a memorandum of law. You do not need to spend examination time creating formal headings such as “To,” “From,” “Date” or “Re.”

7. In addressing the division of powers, distinguish carefully between:

   • the pith and substance of the challenged legislation;

   • whether the legislation falls within a valid federal or provincial head of power;

   • the effect of incidental intrusion into the other level of government’s jurisdiction;

   • the possible application of the ancillary powers doctrine; and

   • the separate question of federal paramountcy where valid federal and provincial laws overlap.

8. Where a Charter right is engaged, identify the right or freedom, analyze whether it has been infringed, consider whether the infringement can be justified under s. 1, and address the appropriate remedy.

9. Do not assume that a finding of federal paramountcy renders provincial legislation invalid. Distinguish validity from operability.

10. Where different provisions of a legislative scheme raise different constitutional issues, analyze them separately rather than assuming that the constitutionality of one provision determines the validity of the entire statute.

11. Do not address Aboriginal or treaty rights, constitutional amendment procedures, or s. 33 of the Charter.

12. Write a clear and organized answer in complete sentences.

QUESTION

FACTS

NeuroVanta Health Inc. (“NeuroVanta”) is an Ontario corporation that designs and manufactures medical devices using targeted electrical stimulation of the brain.

Its principal product is the PulseArc, a headset that delivers precisely calibrated electrical impulses to areas of the brain associated with mood regulation.

PulseArc is intended for use under the supervision of a physician or other specially trained health professional.

It is not sold directly to consumers.

Approximately 80% of NeuroVanta’s sales are to clinics in Ontario. The remaining 20% are to clinics in British Columbia, Alberta and Nova Scotia.

The technology has attracted considerable attention as a possible treatment for severe depression in patients who have not responded to conventional therapies.

Between 2023 and 2025, several other companies began selling more powerful neurostimulation devices directly to consumers through websites and social-media advertisements.

Those devices could be ordered online and used at home without medical supervision.

During that period, Canadian hospitals reported 14 serious neurological incidents associated with unsupervised home use of consumer neurostimulation devices.

Several patients experienced seizures.

Others suffered prolonged disorientation or loss of consciousness.

None of the reported serious incidents involved PulseArc or another device being used in a licensed medical clinic under professional supervision.

Provincial regulation varied considerably.

Some provinces regulated neurostimulation clinics as health facilities.

Others regulated the professionals operating the devices but did not separately regulate the devices themselves.

Two provinces had no legislation specifically directed at neurostimulation.

In 2025, Parliament conducted hearings concerning the emerging industry.

The federal Minister of Health told a parliamentary committee:

“These products increasingly move through a national online market. A device can be advertised in one province, purchased from another and delivered anywhere in Canada within days. Canadians should not face fundamentally different safety standards depending on where they live.”

Several witnesses urged Parliament to distinguish between unsupervised consumer devices and professionally supervised clinical treatment.

A medical association submitted evidence that:

“The existing record discloses materially different risk profiles between unsupervised consumer use and physician-supervised clinical use.”

A proposed amendment would have exempted neurostimulation used exclusively in provincially licensed medical facilities.

The amendment was defeated.

The Minister explained:

“A device that presents neurological risk does not cease to present risk because it is located inside a clinic. A national system should assess the device itself.”

Parliament subsequently enacted the fictional National Neurotechnology Safety Act (“NNSA”).

The preamble states that Parliament is concerned about:

“serious risks to neurological health associated with inadequately tested neurostimulation technologies and the need for consistent minimum standards concerning such technologies throughout Canada.”

The material provisions state:

2. “High-intensity neurostimulation device” means any device intended to alter neurological, cognitive or emotional functioning through electrical or magnetic stimulation above a prescribed intensity.

4(1). No person shall manufacture, import, sell, lease or provide treatment using a high-intensity neurostimulation device unless the device is listed on the National Neurotechnology Registry.

4(2). Subsection (1) applies whether the activity takes place interprovincially or wholly within one province.

5(1). The Minister may list a device where satisfied, on the basis of scientific evidence, that the device is sufficiently safe and therapeutically effective for the proposed use.

7(1). No person shall advertise, promote or otherwise communicate for the purpose of encouraging the therapeutic use of an unlisted high-intensity neurostimulation device.

7(2). No person shall make a therapeutic claim concerning a listed device unless the claim appears in substantially identical form in the federally approved product monograph.

9(1). A person who suffers physical, psychological or economic loss as a result of conduct contrary to s. 4 or s. 7 may bring a civil action against the person responsible for the contravention.

9(2). Liability under subsection (1) does not depend upon proof of negligence.

11. A person who knowingly contravenes s. 4 or s. 7 is guilty of an offence punishable on indictment by a fine or imprisonment for a term not exceeding two years, or both.

The Act establishes a specialized federal regulatory office to maintain the Registry, evaluate scientific evidence and monitor compliance nationally.

Federal officials may conduct inspections and order the removal of unlawfully marketed devices from commerce.

The Minister described s. 9 as:

“an additional deterrent that ensures those who profit from violating national neurotechnology standards bear the losses caused by their conduct.”

Before the federal statute was enacted, Ontario had adopted the fictional Therapeutic Neurostimulation Clinics Act (“TNCA”).

The TNCA establishes a provincial licensing system for clinics and health professionals providing neurostimulation treatment.

The relevant provisions state:

5. The Ontario Neurotherapy College may designate a neurostimulation device as a Provincially Approved Device where satisfied that its supervised clinical use is consistent with acceptable standards of medical practice.

8(1). A licensed neurostimulation clinic shall make a Provincially Approved Device available to a patient where the treating physician certifies that:

(a) the patient suffers from a serious psychiatric or neurological condition;
(b) at least two conventional therapies have been unsuccessful or medically inappropriate; and
(c) use of the device is clinically appropriate.

8(2). Treatment under subsection (1) remains subject to the informed consent of the patient.

9. A device shall not be disqualified from designation or use under this Act merely because the device has not received an approval, licence or listing from another Canadian governmental authority.

The Ontario Minister of Health explained when the TNCA was enacted that its purpose was:

“to regulate the practice of neurostimulation as a health service and to ensure that patients with serious conditions can access treatment under professional supervision.”

In 2025, the Ontario Neurotherapy College approved PulseArc.

The College reviewed two controlled studies, clinical data from approximately 7,000 supervised treatments and evidence from neurologists and psychiatrists.

No serious neurological injury had been reported from supervised PulseArc treatment.

Several researchers nevertheless cautioned that the long-term evidence remained incomplete.

NeuroVanta subsequently applied to have PulseArc placed on the federal Registry.

Federal reviewers accepted that there was no established pattern of serious injury associated with PulseArc.

They nevertheless concluded that the evidence did not yet establish its long-term therapeutic effectiveness to the standard required under s. 5 of the NNSA.

The Minister therefore refused to list PulseArc.

The federal assessment stated:

“The principal deficiency in the application is the absence of sufficient long-term controlled evidence demonstrating sustained therapeutic benefit. The current record does not establish that PulseArc presents a greater immediate neurological risk than comparable devices already used in clinical environments.”

As a result, s. 4 of the NNSA now makes it an offence for an Ontario clinic to provide PulseArc treatment even though PulseArc remains a Provincially Approved Device under the TNCA.

NeuroVanta stopped shipping new PulseArc units but continued supporting clinics that already owned them.

Federal inspectors warned NeuroVanta that technical assistance provided for continued treatment could amount to participation in a contravention of s. 4.

One of the affected patients is Anika Rousseau, a 38-year-old Ontario resident who has experienced severe treatment-resistant depression for several years.

Her psychiatrist, Dr. Martin Okafor, has tried multiple medications and two other recognized therapies.

Two treatments produced serious adverse effects and had to be discontinued.

Dr. Okafor concludes that PulseArc is the only remaining non-invasive treatment he presently considers medically reasonable for Anika.

He certifies that she satisfies all three requirements of s. 8(1) of the TNCA.

The Ontario clinic treating Anika owns a PulseArc unit.

Before enactment of the NNSA, she had completed four supervised treatments and reported significant improvement.

Her treatment was then suspended after the federal prohibition came into force.

Dr. Okafor states that interruption of treatment creates a significant risk of deterioration in Anika’s psychological condition.

He cannot say with certainty whether PulseArc will provide lasting improvement.

The clinic refuses to resume treatment because its medical director does not want its staff exposed to federal criminal liability.

Anika is prepared to provide informed consent and acknowledges the remaining scientific uncertainty.

The federal government responds that Parliament is not obliged to accept Ontario’s assessment of medical risk or efficacy and that allowing individual provincial exemptions would undermine national safety standards.

A second dispute concerns NeuroVanta’s communications with physicians.

NeuroVanta prepared an information package for psychiatrists summarizing peer-reviewed studies concerning PulseArc.

Among other things, it states:

“In two controlled studies, 47% of participating patients experienced remission at 12 weeks.”

It also states:

“No serious neurological adverse event has been identified in approximately 7,000 reported supervised treatments.”

NeuroVanta says both statements accurately reproduce the published scientific literature.

Because PulseArc is not federally listed, s. 7(1) prohibits NeuroVanta from distributing the information for the purpose of encouraging physicians to use PulseArc.

Federal officials have also told NeuroVanta that a planned webinar in which independent researchers would discuss the studies could constitute prohibited promotion if NeuroVanta sponsors the event.

Separately, NeuroVanta manufactures another device called NeuroCalm, which is federally listed.

The approved federal monograph for NeuroCalm states only:

“Clinical studies demonstrate a measurable therapeutic response in some patients.”

NeuroVanta wants to advertise a newly published study reporting a 61% response rate.

Federal officials advise that s. 7(2) prohibits that statement because it does not appear in substantially identical form in the approved product monograph, even if the study itself is methodologically sound.

NeuroVanta argues that Parliament is suppressing truthful scientific and commercial expression rather than merely prohibiting false or misleading advertising.

The federal government responds that medical-product promotion can influence vulnerable patients and prescribing practices and that requiring federally reviewed claims is an important element of the safety scheme.

A third issue concerns s. 9 of the NNSA.

A customer in Ontario recently filed a proposed civil action against another neurotechnology company after suffering an injury from a device used entirely within Ontario.

The claim relies exclusively on s. 9 and does not allege negligence.

NeuroVanta is concerned that the same provision could expose it to civil liability for economic or psychological losses arising from purely intraprovincial dealings.

Ontario has intervened in the litigation and argues that Parliament has created a federal private-law cause of action governing local transactions and civil liability, matters that ordinarily fall within provincial jurisdiction over property and civil rights.

The Attorney General of Canada responds that s. 9 is an enforcement mechanism integrated into the federal safety regime.

Meanwhile, the conflict between the NNSA and the TNCA has become immediate.

Ontario has advised licensed clinics that s. 8 of the TNCA remains in force and that a clinic failing to provide a Provincially Approved Device to an eligible patient may face provincial disciplinary consequences.

Federal officials have advised the same clinics that providing treatment with an unlisted device is an offence under s. 4 of the NNSA.

Ontario’s Attorney General maintains that provincial regulation of medical treatment and professional health services lies at the core of provincial authority over property and civil rights.

The Attorney General of Canada does not dispute Ontario’s general authority to regulate health services but argues that valid federal criminal legislation prevails where simultaneous obedience is impossible.

Ontario responds that the federal legislation is itself invalid because its true character is the detailed regulation of medical devices, clinical treatment, advertising and civil liability rather than the creation of a genuine criminal prohibition.

NeuroVanta and Anika have now retained your firm.

They want to challenge the federal legislation.

Ontario has indicated that it will support their division-of-powers arguments concerning ss. 4 and 9, although it will defend the constitutional validity of the TNCA.

The federal government intends to defend the NNSA in full.

No party alleges that the Charter does not apply to the federal legislation.

Do not address negligence law, product-liability law apart from s. 9, medical malpractice, administrative-law review of the Minister’s individual listing decision, or the constitutional validity of any professional disciplinary proceeding that has not yet occurred.

QUESTION

The senior partner at your firm asks you to prepare a brief but comprehensive memorandum advising NeuroVanta and Anika on the significant Canadian constitutional law issues arising from these events.

Your memorandum should assess the constitutional validity and operation of the relevant federal and provincial legislation, the Charter implications of the federal restrictions on treatment and communication, the strongest competing arguments available to the governments, and the remedies that may realistically follow from any constitutional violation.

Do not merely identify constitutional doctrines. Apply the governing constitutional provisions and assigned Canadian authorities closely to the facts.

100 MARKS

THE BRICKAM EXPLANATION

1. The Analysis Must Begin With Characterization of the Federal Legislation

Before deciding whether Parliament had authority to enact the NNSA, the court must identify the pith and substance of the legislation.

That inquiry looks to both the law’s purpose and its legal and practical effects.

The federal government will characterize the NNSA as legislation directed at protecting Canadians from the health risks associated with inadequately tested neurostimulation technologies through national prohibitions backed by criminal sanctions.

There is substantial support for that characterization.

The preamble expressly refers to serious neurological risks and minimum national safety standards. Parliament heard evidence of seizures, loss of consciousness and other serious injuries. Sections 4 and 7 prohibit specified conduct, while s. 11 attaches penal consequences.

NeuroVanta and Ontario will characterize the statute differently.

They will emphasize that the Act does much more than prohibit dangerous conduct. It establishes a detailed federal registry, regulates which devices doctors may use in clinics, controls the content of medical advertising and scientific claims, creates inspection powers and establishes a private civil cause of action.

Those effects intrude deeply into matters ordinarily associated with medical practice, contracts, local commerce and civil liability.

The existence of substantial provincial effects does not itself invalidate federal legislation.

The question is the dominant characteristic of the law.

The better characterization of the core scheme is likely the regulation, through prohibitions and a federal approval system, of potentially harmful neurostimulation devices in order to protect health and safety.

The more difficult question is whether every provision of the scheme—especially the private cause of action in s. 9—can constitutionally travel with that core.

2. Parliament Has a Strong Criminal-Law Basis for the Core Prohibitions

Section 91(27) of the Constitution Act, 1867 gives Parliament authority over criminal law.

The assigned criminal-law authorities establish that valid criminal legislation ordinarily requires:

• a prohibition;

• backed by a penalty;

• directed toward a legitimate criminal-law public purpose.

Protection of health and public safety are well-established criminal-law purposes.

Sections 4 and 7 expressly prohibit conduct.

Section 11 provides fines and imprisonment.

The federal government can therefore satisfy the formal prohibition-and-penalty structure.

The remaining question is whether the law pursues a genuine criminal-law purpose rather than using penal language to disguise regulation of a provincial matter.

3. Health and Safety Provide a Genuine Criminal-Law Purpose

The evidentiary record strongly assists the federal government.

Parliament was responding to documented neurological injuries associated with an emerging technology.

The concerns were not purely economic.

People had experienced seizures, prolonged disorientation and loss of consciousness.

That places the legislation comfortably within the type of health-and-safety objective capable of supporting criminal legislation.

The Firearms Reference is important because the existence of an elaborate licensing or registration regime does not by itself prevent legislation from qualifying as criminal law.

Parliament may combine prohibition with exemptions, licensing or administrative machinery where those mechanisms define or administer the prohibited conduct.

The fact that the NNSA uses a Registry therefore does not automatically transform the statute into provincial regulatory law.

Likewise, the Genetic Non-Discrimination Act Reference demonstrates that federal criminal law may significantly affect contracts and private relationships where the prohibition is genuinely directed at a valid criminal-law purpose.

The impact on local medical treatment is therefore important, but not necessarily constitutionally decisive.

4. NeuroVanta Has a Stronger Argument Concerning the Breadth of the Federal Scheme Than Concerning Its Basic Subject Matter

The strongest attack is not that Parliament can never legislate concerning neurotechnology.

It plainly can enact criminal prohibitions directed at dangerous products.

The better argument is that this particular scheme regulates beyond the health risk that supplied the criminal-law justification.

The factual record is deliberately important here.

Every reported serious Canadian incident involved unsupervised consumer use.

No serious incident involved PulseArc or another professionally supervised device in a licensed clinic.

Parliament specifically considered and rejected an exemption for clinical use.

That does not necessarily make the law invalid.

Parliament may act preventively and need not wait for harm to occur in every setting before legislating.

But the breadth of the regulatory structure gives NeuroVanta a plausible argument that the dominant purpose has moved from suppressing harmful conduct into comprehensive regulation of medical devices and treatment.

The federal government still has the stronger position on the validity of the basic prohibition.

The health-and-safety objective is real, and a court is unlikely to recharacterize the statute merely because Parliament chose a broad preventive approach.

5. The General Trade and Commerce Power Provides a Possible, but Weaker, Alternative Basis

The federal government may also rely on the general regulation of trade branch of s. 91(2).

The framework associated with General Motors v City National Leasing examines considerations such as:

• whether there is a general regulatory scheme;

• whether the scheme is overseen by a regulatory agency;

• whether the legislation concerns trade as a whole rather than a particular local industry;

• whether the provinces would be constitutionally incapable of enacting the scheme; and

• whether failure of one or more provinces to participate would jeopardize the scheme elsewhere.

Some features support federal jurisdiction.

The NNSA creates a national regulatory scheme administered by a specialized federal body.

Neurotechnology products move across provincial borders and through online markets.

The provinces have adopted materially different regulatory approaches.

The federal government can therefore argue that inconsistent provincial standards undermine a genuinely national market.

Other considerations cut the opposite way.

The statute regulates one relatively specific class of products rather than trade as a whole.

Provincial governments plainly possess significant capacity to regulate:

• clinics;

• health professionals;

• local product sales;

• treatment standards; and

• intraprovincial civil liability.

The Securities Reference cautions against converting the general trade and commerce power into authority over any economically important industry simply because national uniformity would be convenient.

The trade-and-commerce basis is therefore less secure than the criminal-law basis.

The core provisions need not satisfy both.

If the law is valid criminal legislation, failure under the general trade and commerce branch does not invalidate it.

6. Section 9 Raises a Distinct Division-of-Powers Problem

Section 9 creates a statutory civil cause of action.

A person suffering physical, psychological or economic loss from conduct contrary to ss. 4 or 7 can recover without proving negligence.

Standing alone, the creation of rights and liabilities between private parties in a local transaction looks strongly like property and civil rights in the province under s. 92(13).

The federal government therefore needs a constitutional basis for attaching this private-law remedy to the broader federal scheme.

That engages the ancillary powers doctrine.

7. The Ancillary Powers Doctrine May Save Section 9, but Its Validity Is Less Certain Than the Core Prohibitions

The framework reflected in General Motors and Lacombe asks whether a provision that intrudes into the other level of government’s jurisdiction is sufficiently integrated into an otherwise valid legislative scheme.

The required strength of the connection varies with the seriousness of the intrusion.

Section 9 is not a trivial procedural detail.

It creates substantive civil liability, including for purely intraprovincial transactions and economic loss, without requiring proof of negligence.

That is a meaningful intrusion into provincial private law.

The federal government argues that the provision:

• deters contraventions;

• strengthens compliance;

• compensates victims; and

• reinforces the criminal-law scheme.

Those connections are real.

The difficulty is whether a private no-fault civil remedy is sufficiently necessary or integral to enforcement of the federal prohibitions.

Sections 4, 7 and 11 can operate perfectly well as criminal prohibitions without s. 9.

Federal inspectors and penal sanctions already exist.

That weakens the claim that this private cause of action is essential to the scheme.

A court could therefore conclude that the core NNSA is valid while s. 9 independently exceeds Parliament’s authority.

This is precisely why each provision must be analyzed separately.

8. If Section 9 Is Invalid, It Is Potentially Severable

The NNSA does not appear structurally dependent on the civil cause of action.

The Registry, prohibitions, enforcement powers and offences can continue functioning without s. 9.

If s. 9 cannot be supported by the ancillary powers doctrine, the constitutional defect therefore need not invalidate the entire statute.

Severance would be a realistic remedy.

9. Ontario’s TNCA Is Prima Facie Valid Provincial Legislation

The TNCA has a very different dominant character.

It regulates:

• health clinics;

• health professionals;

• conditions under which treatment may be offered;

• patient access; and

• standards of medical practice.

Those matters fall comfortably within provincial legislative authority, particularly property and civil rights in the province under s. 92(13), together with the provinces’ authority over matters of a local nature.

The fact that Ontario’s law concerns the same physical devices as the federal statute does not make it invalid.

Canadian federalism permits substantial overlap.

The same factual activity may possess both federal and provincial aspects.

That is the double aspect principle reflected in cases such as Canadian Western Bank.

The more important question is therefore not whether Ontario may regulate clinical neurostimulation in general.

It may.

The question is what happens where valid provincial rules conflict with valid federal prohibitions.

10. Validity Must Be Determined Before Paramountcy

The federal government cannot invoke paramountcy simply because it prefers its rules.

Federal paramountcy presupposes the existence of:

• valid federal legislation; and

• valid provincial legislation.

If s. 4 were outside federal jurisdiction, there would be no valid federal rule capable of rendering the Ontario provision inoperative.

Conversely, if both statutes are valid, the court then asks whether they conflict.

Keeping these analytical stages separate is essential.

11. There Is a Strong Case of Operational Conflict Between Section 4 of the NNSA and Section 8 of the TNCA

Federal paramountcy applies where there is an actual operational conflict because compliance with one law requires violation of the other.

That problem is acute here.

Ontario s. 8 says that a licensed clinic shall make a Provincially Approved Device available where the statutory conditions are met.

Anika meets those conditions.

PulseArc remains provincially approved.

Federal s. 4 says that no person may provide treatment using PulseArc because it is not federally listed.

The Ontario clinic therefore faces two commands:

provide the treatment

and

do not provide the treatment.

It cannot comply with both.

That is a classic operational conflict.

Assuming federal s. 4 is valid, the provincial requirement must be inoperative to the extent of the conflict.

The TNCA itself is not thereby constitutionally invalid.

12. Section 9 of the TNCA Presents a Slightly Different Paramountcy Question

Ontario s. 9 states that absence of approval from another Canadian authority does not itself disqualify a device from provincial designation or use.

Viewed in isolation, that provision may merely say:

Ontario will conduct its own provincial approval analysis.

Mere provincial permission does not always conflict with a federal prohibition.

The reasoning in Rothmans, Benson & Hedges illustrates the distinction between one legislature permitting something and the other prohibiting it.

A person can often obey both laws simply by refraining from the federally prohibited conduct.

Here, however, s. 9 does not operate in isolation.

Combined with the mandatory-access requirement in s. 8, Ontario has created a regime that affirmatively requires use of devices whose federal approval may have been refused.

That strengthens the federal argument considerably.

13. Frustration of Federal Purpose Also Supports Paramountcy

The second branch of paramountcy applies where operation of provincial law would frustrate the purpose of valid federal legislation.

The federal purpose must be established with sufficient precision.

The federal government can identify a clear purpose:

high-intensity neurostimulation devices are not to be used therapeutically until they satisfy the federal listing standard.

Ontario’s regime expressly allows provincial approval despite absence of federal listing and then requires access in qualifying cases.

That directly undermines the federal decision to withhold market or treatment access until the national standard has been met.

Accordingly, even if a court found some technical means of avoiding operational conflict, frustration of federal purpose would provide an additional strong paramountcy argument.

14. Paramountcy Does Not Erase Ontario’s Regulatory Scheme

The proper consequence is limited.

Ontario remains free to regulate:

• clinic licensing;

• professional qualifications;

• consent requirements;

• treatment conditions; and

• devices that may lawfully be used consistently with federal law.

Only the provincial provisions that conflict with the valid federal prohibition become inoperative to the extent of the conflict.

That distinction preserves as much of each legislature’s valid enactment as possible.

The Charter Issues

15. NeuroVanta’s Scientific and Commercial Communications Are Protected Expression

Section 2(b) protects freedom of expression.

The protection is broad.

Under Irwin Toy, expression generally includes activity that conveys or attempts to convey meaning, subject to limited categories outside protection.

Commercial expression is not excluded merely because it is motivated by profit.

NeuroVanta’s communications plainly convey meaning.

The proposed physician information package conveys scientific findings concerning PulseArc.

The webinar conveys research and medical information.

The proposed NeuroCalm advertisement communicates the results of a clinical study.

All therefore fall within the protected sphere of expression.

16. Section 7 of the NNSA Infringes Section 2(b)

The federal restrictions are directed expressly at communicative content and purpose.

Section 7(1) prohibits communications designed to encourage therapeutic use of an unlisted device.

Section 7(2) limits therapeutic claims to language appearing in the federally approved monograph.

The restriction therefore does not merely incidentally affect expression through regulation of conduct.

Its purpose and effect are to control what may be communicated.

A s. 2(b) infringement is straightforward.

The constitutional dispute moves to s. 1.

17. The Government Has a Pressing and Substantial Objective

The federal objective is strong.

Health-product advertising can influence treatment decisions.

Neurostimulation potentially affects neurological functioning.

Parliament has evidence of serious injuries associated with some devices.

Preventing dissemination of unsafe or inadequately substantiated therapeutic claims is therefore a pressing and substantial objective.

NeuroVanta is unlikely to succeed by attacking the importance of the legislative goal.

The stronger issues arise at proportionality.

18. There Is a Rational Connection Between Control of Therapeutic Claims and the Safety Objective

Requiring claims to undergo federal scrutiny can rationally reduce:

• misleading promotion;

• premature adoption of inadequately tested technology; and

• reliance on claims unsupported by the federal evidentiary process.

Likewise, restricting promotion of an unlisted device is rationally connected to a system that prohibits therapeutic use of that device.

The rational-connection requirement is therefore likely satisfied.

19. Minimal Impairment Is Much More Difficult for the Federal Government

The breadth of s. 7 creates a serious problem.

The law does not merely prohibit:

• false claims;

• misleading advertising;

• consumer advertising; or

• claims unsupported by scientific evidence.

Section 7(1) can prevent distribution of accurate peer-reviewed data to physicians concerning an unlisted device.

It may also prohibit a scientific webinar involving independent researchers if NeuroVanta sponsors it for a promotional purpose.

Section 7(2) prohibits NeuroVanta from communicating an accurate 61% response rate concerning a federally approved device merely because the exact statement does not appear in the existing federal monograph.

Those facts allow NeuroVanta to identify plausible less impairing alternatives.

Parliament could regulate:

• false or misleading claims;

• claims lacking reasonable scientific support;

• direct-to-consumer advertising;

• high-risk promotional practices; or

• communications without prescribed warnings.

It could also distinguish promotional communications directed at vulnerable consumers from technical information directed to health professionals.

The government will emphasize the need for consistent pre-clearance and the difficulty of policing scientific claims after publication.

Courts also afford legislatures some latitude where complex health and regulatory judgments are involved.

But deference does not eliminate the minimal-impairment requirement.

A blanket rule suppressing truthful, scientifically supported information may go further than reasonably necessary.

20. Overall Proportionality Also Raises Serious Concerns

The salutary effects include:

• consistent health information;

• reduced risk of misleading therapeutic claims; and

• stronger control over new medical technologies.

The deleterious effects include suppression of:

• truthful scientific information;

• communication between manufacturers and physicians;

• discussion of emerging research; and

• potentially useful information concerning approved products.

The fact that even accurate communications can be prohibited is significant.

A court could reasonably conclude that at least portions of s. 7 fail s. 1.

The challenge is stronger as applied to truthful professional and scientific communications than it would be to misleading direct-to-consumer advertising.

21. Anika Has a Serious Section 7 Charter Claim

Anika’s argument engages a different provision: s. 7 of the Charter.

Section 7 protects life, liberty and security of the person and prevents deprivations that are inconsistent with the principles of fundamental justice.

The assigned decisions in PHS, Bedford and Carter demonstrate that state interference with access to medical treatment or health-related decision-making can engage s. 7 where the law creates or materially increases serious risks to an individual’s physical or psychological integrity.

Anika is not merely requesting that government fund a preferred therapy.

Federal law actively makes it a criminal offence for her clinic to provide treatment that would otherwise lawfully be available under provincial law.

That state prohibition is important.

22. Security of the Person Is Strongly Engaged

Dr. Okafor states that interruption of PulseArc treatment creates a significant risk of deterioration in Anika’s psychological condition.

She had already begun treatment and reported substantial improvement.

The prohibition therefore affects her physical or psychological integrity in a serious, non-trivial manner.

That is capable of engaging security of the person.

There may also be a liberty dimension because the legislation limits important medical decisions that would otherwise be made between Anika and her physician.

The security interest is the stronger claim.

23. This Is Not Merely a Claim to a Positive Government Benefit

The government may argue that s. 7 does not constitutionalize access to any treatment a patient and physician prefer.

That proposition has force.

The Charter does not generally require the state to provide every available medical treatment.

But that is not exactly Anika’s claim.

Ontario has created a lawful clinical system.

Her physician is prepared to treat her.

The clinic owns the device.

Anika is willing to consent.

The federal state has intervened with a prohibition backed by imprisonment.

Her argument is therefore one against a state-created barrier, not simply a demand that government supply a benefit.

That distinction materially strengthens her reliance on the s. 7 cases.

24. The Real Section 7 Question Is Whether the Deprivation Complies With Fundamental Justice

Engagement of life, liberty or security does not by itself invalidate legislation.

Anika must establish that the deprivation is contrary to a principle of fundamental justice.

The strongest possibilities are:

• arbitrariness;

• overbreadth; and

• gross disproportionality.

These concepts must be applied separately.

25. Arbitrariness Is Probably Anika’s Weakest Argument

A law is arbitrary where there is no rational connection between its effect on the claimant and its objective.

The federal objective is to protect people against inadequately tested neurostimulation technology.

PulseArc has not satisfied the federal listing standard.

Its long-term therapeutic effectiveness remains uncertain.

There is therefore at least a rational connection between requiring federal approval and preventing use before the evidentiary standard has been satisfied.

The fact that Ontario reached a different scientific conclusion does not itself make the federal rule arbitrary.

The federal government has the stronger argument on arbitrariness.

26. Overbreadth Presents a Much Stronger Challenge

Overbreadth asks whether the law goes further than necessary by capturing conduct that bears no meaningful connection to its objective.

The underlying evidence is important.

The serious incidents motivating Parliament all involved unsupervised home use.

There were no reported serious injuries from PulseArc or comparable professionally supervised treatment.

Parliament was expressly told that supervised clinical use had a materially different risk profile.

It nevertheless extended the criminal prohibition to all treatment using an unlisted device.

That gives Anika a credible argument that the law captures a category of conduct beyond the mischief Parliament sought to address.

The federal response is also substantial.

Parliament’s concern was not limited to previously documented injuries.

The statutory purpose includes protection against inadequately tested technologies.

A lack of known serious injuries does not prove safety.

Moreover, the listing process examines effectiveness as well as immediate harm.

The government can argue that supervised use still creates neurological risks and that the distinction between consumer and clinical use does not eliminate the need for national pre-market assessment.

The issue is therefore genuinely contestable.

27. The Federal Refusal Based Primarily on Efficacy Evidence Strengthens Anika’s Position

The federal assessment stated that PulseArc was not rejected because reviewers identified a greater immediate neurological danger.

The principal deficiency was lack of sufficient long-term evidence of sustained therapeutic benefit.

That matters.

If the law is defended primarily as a measure preventing serious neurological harm, criminally prohibiting a physician from using a device because its long-term efficacy has not been demonstrated may appear broader than the safety rationale would suggest.

The government can answer that ineffective medical treatment can itself cause harm by delaying effective care and exposing patients to uncertain interventions.

But the factual distinction remains important to the proportionality of the prohibition as applied to Anika.

28. Gross Disproportionality Is Possible but Harder to Establish

Gross disproportionality asks whether the impact on the individual is so severe relative to the law’s objective that it is fundamentally out of sync with that objective.

Anika has unusually strong facts.

She suffers from a serious condition.

Multiple conventional treatments have failed or caused serious adverse effects.

Her physician identifies PulseArc as the only remaining reasonable non-invasive treatment.

She had already begun improving before federal law interrupted treatment.

Against that, the government invokes an important health objective concerning a developing neurological technology.

Gross disproportionality sets a demanding threshold.

Anika’s argument is meaningful, but overbreadth is likely the cleaner route.

29. A Section 7 Violation Would Be Difficult to Justify Under Section 1

Section 7 and s. 1 remain analytically distinct.

However, where a law has been found arbitrary, overbroad or grossly disproportionate, the same defect will usually make justification under s. 1 difficult.

If the court concludes that the blanket prohibition captures medically supervised conduct unrelated to the law’s valid protective purpose, it will be difficult for the government to show that the same excess is minimally impairing.

The government can nevertheless rely on:

• scientific uncertainty;

• the seriousness of neurological risks;

• the evolving nature of the technology; and

• the difficulty of designing separate standards for supervised and unsupervised use.

The outcome should not be treated as automatic.

30. The Court Must Keep the Federalism and Charter Analyses Separate

It is possible that:

• s. 4 is within federal jurisdiction, yet violates Anika’s Charter rights;

• s. 7 is valid federal criminal legislation, yet violates freedom of expression;

• s. 9 falls outside federal jurisdiction even if the rest of the Act is valid.

Those are separate constitutional questions.

A law does not become valid under the Charter because Parliament had legislative authority to enact it.

Nor does a Charter violation establish that Parliament lacked a head of power.

Strong constitutional analysis preserves these distinctions.

Remedies

31. An Ultra Vires Provision Is of No Force or Effect Under Section 52(1)

Section 52(1) of the Constitution Act, 1982 provides that inconsistent law is, to the extent of the inconsistency, of no force or effect.

If the court finds that s. 9 exceeds Parliament’s legislative authority and cannot be sustained by ancillary powers, the appropriate remedy would likely be invalidation of s. 9, not the entire NNSA.

The same principle applies if some other discrete provision exceeds federal power.

The remedy should correspond to the constitutional defect.

32. Paramountcy Produces Inoperability, Not Invalidity

If both s. 4 of the NNSA and ss. 8–9 of the TNCA are constitutionally valid but conflict, federal paramountcy does not erase Ontario’s statute.

The conflicting provincial provisions become inoperative to the extent of the conflict.

If the federal prohibition were later repealed or invalidated, the provincial provisions could again operate without requiring Ontario to reenact them.

That distinction is important.

33. A Charter Violation May Require More Tailored Relief

If the advertising provisions violate s. 2(b), the court must determine the appropriate constitutional remedy.

Possible approaches include:

• striking the offending provision;

• severing unconstitutional portions;

• reading down the scope of the prohibition where consistent with legislative intent; or

• temporarily suspending invalidity where immediate nullification would create serious regulatory consequences.

The remedial jurisprudence in Vriend and Ontario (Attorney General) v G emphasizes that the court must select a remedy responsive to the constitutional defect while respecting the institutional role of the legislature.

For example, if the defect lies principally in suppressing truthful professional communications, a court may have to consider whether that unconstitutional reach can be separated from legitimate restrictions on misleading promotion.

It should not casually redesign an entire medical-advertising regime from the bench.

34. Anika’s Remedy Requires Particular Attention to Timing

A purely suspended declaration could have serious consequences for Anika.

If the provision continues operating during a lengthy suspension, she remains unable to receive the treatment while her condition may deteriorate.

That creates a potential argument for individualized interim or constitutional relief while Parliament responds.

At the same time, courts are cautious about creating broad judicial exemptions from legislation whose constitutional validity remains under consideration.

The appropriate remedy would depend on the exact finding of unconstitutionality and the evidence concerning Anika’s medical circumstances.

Section 24(1) may be relevant to an individual remedy, while s. 52(1) remains the principal mechanism where the source of the violation is the legislation itself.

35. Constitutional Damages Are Not the Natural Primary Remedy

Nothing in the facts presently suggests that federal officials acted maliciously or in bad faith.

The dispute concerns enforcement of legislation whose constitutionality is contested.

Although Ward establishes the possibility of Charter damages in appropriate circumstances, damages are unlikely to be the central remedy here.

The principal objectives are:

• determining the validity of the legislation;

• preventing unconstitutional restrictions from continuing; and

• clarifying which federal and provincial rules govern treatment.

Declaratory and constitutional remedies are therefore much more important than damages.

36. Overall Advice

The federal government has a strong argument that the core NNSA is valid criminal legislation.

The Act contains genuine prohibitions and penalties and responds to documented health risks.

NeuroVanta’s argument that the statute impermissibly regulates local medicine is significant, particularly because the legislation reaches supervised clinical treatment, but it probably does not defeat the validity of the core scheme.

The general trade and commerce power provides a less certain alternative basis because the statute targets a specific industry and the provinces possess substantial regulatory capacity.

Section 9 is considerably more vulnerable.

A no-fault federal civil cause of action governing purely local losses intrudes directly into provincial property and civil rights. Its survival depends on the ancillary powers doctrine, and its relationship to the core federal prohibitions may not be sufficiently strong given the degree of intrusion.

Ontario’s TNCA is valid provincial health and professional regulation.

However, if federal s. 4 is valid, the mandatory provincial treatment obligation is likely inoperative under federal paramountcy wherever Ontario requires conduct that federal law prohibits.

NeuroVanta also has a substantial s. 2(b) challenge to the federal communication restrictions.

The prohibition extends beyond false or misleading advertising and captures truthful scientific and professional communications. The federal objective is pressing, but the breadth of the restriction creates a serious minimal-impairment problem.

Anika has a serious s. 7 claim.

The federal prohibition directly prevents access to treatment that would otherwise be medically and provincially available. Security of the person is strongly engaged.

The law is probably not arbitrary, but its extension to professionally supervised treatment—particularly where the underlying serious incidents arose exclusively from unsupervised consumer use—creates a credible overbreadth argument.

The likely constitutional outcome is therefore not an all-or-nothing result.

The strongest analysis distinguishes among the individual statutory provisions and constitutional doctrines:

• the core federal prohibitions are likely within Parliament’s criminal-law authority;

• the federal civil cause of action is constitutionally vulnerable;

• the Ontario clinical regime is valid but partly inoperative where it conflicts with valid federal law;

• the federal advertising restrictions face a serious s. 2(b) challenge; and

• the prohibition on Anika’s supervised treatment gives rise to a substantial, though genuinely contestable, s. 7 challenge.

Brickam’s Suggested Marking Approach

Issue	What a strong answer should address	Marks
Pith and substance of the NNSA	Purpose and effects; federal health/safety characterization; competing characterization as detailed regulation of medical treatment, advertising and private transactions; incidental provincial effects	10
Federal criminal-law power	Prohibition and penalty structure; valid criminal-law purpose; health and safety; significance of the licensing/Registry regime; application of the assigned criminal-law authorities including the Firearms and Genetic Non-Discrimination references	15
General trade and commerce power	General Motors framework; national regulatory scheme; regulatory agency; one-industry problem; provincial capacity; interprovincial online market; Securities Reference considerations	8
Section 9 and ancillary powers	Private civil liability as property and civil rights; seriousness of intrusion; integration with otherwise valid federal scheme; deterrence/compensation arguments; General Motors/Lacombe analysis; severability	8
Validity of Ontario’s TNCA / double aspect	Provincial regulation of health services, professions and local treatment; s. 92(13); overlapping federal and provincial aspects; Canadian Western Bank principles	7
Federal paramountcy	Validity before operability; operational conflict between federal prohibition and provincial mandatory treatment; separate analysis of provincial s. 9; frustration of federal purpose; limited consequence of inoperability	10
Freedom of expression — s. 2(b)	Scientific and commercial expression; Irwin Toy framework; direct content-based restriction; application to physician package, webinar and NeuroCalm advertising	8
Section 1 justification of expression limits	Pressing objective; rational connection; minimal impairment; truthful versus misleading expression; professional versus consumer communications; less impairing alternatives; final proportionality; Oakes/Hutterian analysis	10
Section 7 — engagement	State-caused deprivation; security of person and possible liberty interest; distinction between positive entitlement and state prohibition; PHS/Carter/Bedford principles	7
Section 7 — principles of fundamental justice	Arbitrariness, overbreadth and gross disproportionality considered separately; significance of supervised-use evidence, PulseArc safety record and federal efficacy concerns; strongest government responses	10
Section 1 in relation to s. 7	Difficulty justifying a fundamental-justice defect; scientific uncertainty and regulatory arguments; relationship between overbreadth and minimal impairment	3
Constitutional remedies	s. 52 invalidity; severance; distinction between invalidity and paramountcy inoperability; Charter remedial tailoring; suspended declarations; possible individual relief; limited role for Ward damages	4
TOTAL		100